Company Overview
About Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Business Model & Competitive Advantage
Moderna's scientific platform is based on the revolutionary insight that mRNA can be designed to instruct cells to produce virtually any protein—including viral antigens for vaccines, antibodies, or therapeutic proteins—enabling a programmable medicine approach. The mRNA technology validated through COVID vaccine development creates a platform applicable to infectious disease, oncology, rare diseases, and cardiovascular conditions. Key 2024 milestones include FDA approval of mRESVIA, an mRNA RSV vaccine for adults 60+—the first respiratory disease vaccine beyond COVID—and the personalized cancer vaccine (PCV) developed with Merck using tumor-specific neoantigens delivered via mRNA, which demonstrated 44% reduction in recurrence in a melanoma Phase 2 trial when combined with Keytruda.
Competitive Landscape 2025–2026
In 2025-2026, Moderna's pipeline execution will determine whether the company can establish a sustainable commercial franchise beyond COVID. Next-generation vaccines under development include a combined flu/COVID mRNA combination vaccine, an mRNA cytomegalovirus (CMV) vaccine, latent tuberculosis treatment, and a next-generation pandemic preparedness portfolio. The personalized cancer vaccine partnership with Merck—which exercised its option for shared development rights in 2023—could generate blockbuster revenues if Phase 3 trials confirm Phase 2 results across multiple tumor types. Moderna competes with BioNTech (BNTX, Pfizer's COVID partner), Pfizer, and traditional vaccine makers GSK and Sanofi as mRNA platforms expand beyond COVID into established vaccine markets.
Company Timeline
Major milestones in Moderna's journey
Leadership Team
Meet the leaders behind Moderna
Stéphane Bancel
Stéphane Bancel has served as Chief Executive Officer of Moderna since 2011 and is a member of the company's Board of Directors. A French entrepreneur with a Master's degree in chemical engineering from the École Centrale Paris and an MBA from Harvard Business School, Bancel had no prior experience with mRNA when he joined Moderna but brought valuable operational and strategic expertise. Before Moderna, he served as CEO of French diagnostics company bioMérieux, where he led significant expansion and operational improvements. Under Bancel's leadership, Moderna raised an unprecedented $2 billion in private funding, completed a record-breaking IPO in 2018, and navigated the company through the development and global deployment of its COVID-19 vaccine. His strategic vision emphasizes building a technology platform rather than individual products, investing heavily in manufacturing capabilities, and advancing a diversified pipeline across multiple therapeutic areas. Bancel's leadership during the COVID-19 pandemic demonstrated his ability to make rapid decisions under pressure while maintaining scientific rigor. He has guided Moderna through its transition from a pre-revenue biotech to a profitable company and is now leading cost reduction initiatives and strategic prioritization to ensure long-term sustainability as the company advances its broader pipeline beyond COVID-19.
James Mock
James Mock has served as Chief Financial Officer of Moderna since 2022, overseeing the company's financial, business development, and business services functions. Mock joined Moderna during a critical transition period as COVID-19 vaccine revenues began declining from pandemic peaks, requiring strategic financial planning to balance investment in pipeline development with cost discipline. Under his leadership, Moderna reduced costs by 27% in 2024 compared to 2023 and announced a goal of achieving $1.1 billion in savings by 2027. Mock is responsible for financial reporting, treasury management, investor relations, business development partnerships, and strategic planning. His role includes managing Moderna's substantial cash resources generated from COVID-19 vaccine sales while ensuring appropriate capital allocation to advance late-stage pipeline programs with the highest commercial potential. Mock emphasizes financial discipline and prioritization, making tough decisions about which programs to advance, pause, or discontinue based on scientific data, market potential, and resource requirements. His financial stewardship is critical as Moderna transitions from dependence on COVID-19 revenues to a diversified revenue base from multiple approved products.
Stephen Hoge
Stephen Hoge serves as President of Moderna and oversees the company's Research & Development organization, making him responsible for the scientific and clinical development of Moderna's entire pipeline. Hoge joined Moderna in 2012 and has been instrumental in building the company's mRNA platform and advancing programs from early research through clinical development and regulatory approval. As a physician-scientist with an MD from the University of California, San Francisco, Hoge brings deep scientific expertise and clinical insight to his role. He played a central role in the rapid development of Moderna's COVID-19 vaccine, making critical decisions about vaccine design, clinical trial protocols, and regulatory strategy. Hoge oversees a research organization spanning discovery biology, preclinical development, clinical development, regulatory affairs, and medical affairs. He is responsible for scientific prioritization decisions, ensuring that Moderna's resources are focused on programs with the greatest likelihood of clinical and commercial success. Hoge's leadership extends to strategic partnerships and collaborations, where his scientific credibility and vision help attract partners and investment in Moderna's platform.
Brad Miller
Brad Miller has served as Chief Information Officer of Moderna since January 2023, responsible for the company's information technology strategy, infrastructure, and digital transformation initiatives. Prior to joining Moderna, Miller served as Executive Vice President and Chief Information Officer of Capital One, where he led technology operations for one of America's largest banks. At Moderna, Miller oversees IT systems that support research and development, manufacturing, quality control, commercial operations, and corporate functions. He is leading Moderna's adoption of advanced technologies including artificial intelligence, machine learning, and cloud computing to accelerate drug discovery and development. Miller's collaboration with IBM on AI and quantum computing applications represents Moderna's commitment to becoming a digitally-enabled biotechnology company. His expertise in large-scale systems implementation and digital innovation is critical as Moderna expands from a single-product company to a diversified biopharmaceutical enterprise requiring sophisticated technology infrastructure. Miller's role includes cybersecurity, data management, enterprise software systems, and digital tools that enhance scientific productivity and operational efficiency.
Jared Collins
Jared Collins serves as Chief Technical Operations and Quality Officer at Moderna, playing a pivotal role in overseeing the company's technical operations and ensuring the highest quality standards for all products and manufacturing processes. Collins is responsible for manufacturing operations, supply chain management, quality assurance, quality control, and regulatory compliance across Moderna's global manufacturing network. His role became especially critical during the COVID-19 pandemic when Moderna needed to rapidly scale production from zero to billions of doses while maintaining stringent quality standards. Collins oversees manufacturing facilities in Massachusetts, Switzerland, Canada, and partner sites globally, ensuring consistent production of mRNA medicines that meet or exceed regulatory requirements. He leads technology transfer activities as new products move from development to commercial manufacturing, process optimization initiatives to improve efficiency and reduce costs, and quality systems that ensure patient safety. Collins's expertise in biopharmaceutical manufacturing and quality operations is essential as Moderna expands beyond COVID-19 vaccines to additional products requiring different formulations, presentations, and manufacturing processes.
Shannon Thyme Klinger
Shannon Thyme Klinger serves as Chief Legal Officer and Corporate Secretary at Moderna, overseeing the company's legal strategies, ensuring compliance with regulatory standards, and managing intellectual property, litigation, corporate governance, and transactional matters. Klinger's role has been particularly important as Moderna has navigated complex legal and regulatory environments across multiple countries during the COVID-19 pandemic, negotiated supply agreements with governments and international organizations, and defended the company's intellectual property in patent disputes including the November 2024 lawsuit filed by GSK. She leads a legal team responsible for regulatory affairs, compliance, contracts, employment law, securities law, and corporate governance. Klinger advises the Board of Directors and executive leadership on legal risks and strategies, ensuring that Moderna's operations comply with applicable laws and regulations. Her expertise in biopharmaceutical law, intellectual property, and corporate transactions is critical as Moderna enters new markets, forms strategic partnerships, and commercializes additional products beyond its initial COVID-19 vaccine.
Kate Cronin
Kate Cronin has served as Moderna's Chief Brand Officer since July 2021, responsible for the company's brand strategy, corporate communications, public affairs, and reputation management. Cronin joined Moderna during a period of intense public attention following the success of its COVID-19 vaccine, when the company needed to transition from a relatively unknown biotech to a globally recognized brand. She oversees corporate branding, external communications, media relations, public affairs, patient advocacy relationships, and crisis communications. Cronin's role includes shaping public perception of Moderna as an innovative biotechnology company committed to transforming medicine through mRNA technology, not just a COVID-19 vaccine manufacturer. She leads communications around pipeline programs, financial results, corporate initiatives, and the company's broader mission. Cronin's expertise in brand building and stakeholder communications is essential as Moderna seeks to maintain public trust, attract talent, engage with policymakers, and build awareness of its expanding pipeline beyond COVID-19.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
Moderna is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $3200M in revenue, Moderna operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
YouShift
YouShift is a United States-based AI healthcare workforce management platform — building the operating system for healthcare staffing starting with AI-powered scheduling agents that replace the comple
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Dusty Robotics
Dusty Robotics is a Mountain View, California-based construction robotics company — backed with $69.5 million in total funding from Root Ventures, Scale Venture Partners, Canaan Partners, GRIDS Capita
Compare Moderna with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Moderna? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Moderna Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Moderna vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →